Cost-Effectiveness Analysis of MammaPrint^® to Guide the Use of Endocrine Therapy in Patients with Early-Stage Breast Cancer.

ABSTRACT:

Background

Gene expression profiling tests can predict the risk of disease recurrence and select patients who are expected to benefit from therapy, while allowing other patients to forgo therapy. For breast cancers, these tests were initially designed to tailor chemotherapy decisions, but recent evidence suggests that they may also guide the use of endocrine therapy. This study evaluated the cost effectiveness of a prognostic test, MammaPrint^®, to guide the use of adjuvant endocrine therapy in patients eligible according to Dutch treatment guidelines.

Methods

We constructed a Markov decision model to calculate the lifetime costs (in 2020 Euros) and effects (survival and quality-adjusted life-years) of MammaPrint^® testing versus usual care (endocrine the

SUBMITTER: Luyendijk M 

PROVIDER: S-EPMC10322767 | biostudies-literature | 2023 Aug

REPOSITORIES: biostudies-literature